Dr. Issels explains his use of the LuxSana far infrared sauna in his treatment of chronic diseases and cancer.
Thelma Vandiver is a 71 year old lung cancer survivor. She’s practically cancer free!
Bill Darlington tells of his amazing recovery from prostate and bone cancer.
Wikipedia on infrared sauna’s:
An infrared sauna produces radiant energy, which is the same as the heat from the sun, only minus the harmful ultraviolet rays. This type of heating element is derived from technology developed by Dr. Tadashi Ishikawa in 1965, a member of the Research and Development Department of Fuji Medical…… MORE
Dr. Elizabeth Repasky states in an article at Storming Media, “we observed that a long term, low temperature hyperthermia treatment (fever-range exposure) can induce a substantial amount of heat shock proteins in the patients’ breast tumor. This treatment also appears to cause a dramatic increase in the killing of tumors by host NK cells. We are aggressively pursuing this unexpected finding as part of the goals related the use of heat shock proteins in Aim 3”. “Hyperthermia also seems to ‘jump-start the immune response’ at least in mice, said Dr. Repasky, an immunology professor at the Rosewell Park Cancer Institute in Buffalo, she is now looking at the effects in humans. Just as a fever with the flu may boost immune response, so might hyperthermia, a kind of artificial fever.” Dr. Repasky also lectured on the subject of hyperthermia at the University of Minnesota October the 21st, 2008. Dr. Repasky, is a member of the Editorial Board of the International Journal of Hyperthermia, the American Association for Cell Biology, Society of Leukocyte Biology, Society for Biologic Therapy, and North American Hyperthermia Society and has done extensive research on the use of hperthermia and cancer treatment.
Current far-infrared research:
1: Med Oncol. 2008;25(2):229-37. Epub 2007 Oct 30.
The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A.
Department of Oral and Maxillofacial Anatomy, Medical Science for Oral and Maxillofacial Regeneration, Graduate School of Health Biosciences, University of Tokushima, 3-18-15 Kuramoto, Tokushima 770-8504, Japan.
We developed a tissue culture incubator that can continuously irradiate cells with far-infrared radiation (FIR) of wavelengths between 4 and 20 microm with a peak of 7-12 microm, and found that FIR caused different inhibiting effects to five human cancer cell lines, namely A431 (vulva), HSC3 (tongue), Sa3 (gingiva), A549 (lung), and MCF7 (breast). Then, in order to make clear the control system for the effect of FIR, the gene expression concerned to the inhibition effect by FIR were analyzed. In consequence, basal expression level of HSP70A mRNA was higher in A431 and MCF7 cells than in the FIR-sensitive HSC3, Sa3, and A549 cells. Also, the over expression of HSP70 inhibited FIR-induced growth arrest in HSC3 cells, and an HSP70 siRNA inhibited the proliferation of A431 cells by irradiation with FIR. These results indicate that the effect of a body temperature range of FIR suppressing the proliferation of some cancer cells is controlled by the basal expression level of heat shock protein (HSP) 70A. This finding suggested that FIR should be very effective medical treatment for some cancer cells which have a low level of HSP70. Still more, if the level of HSP70 in any cancer of a patient was measured, the effect of medical treatment by FIR can be foreseen for the cancer.
PMID: 17968683 [PubMed – indexed for MEDLINE]
1: Anticancer Res. 1999 Sep-Oct;19(5B):4125-30.
Inhibition by whole-body hyperthermia with far-infrared rays of the growth of spontaneous mammary tumours in mice.
Experimental Animal Research Laboratory, Meiji University, Kawasaki, Japan.
To evaluate possible therapeutic benefits of irradiation with far-infrared rays (FIR) on breast cancer, we examined combined effects of the chronic exposure to FIR at ambient temperature (26.5-27.5 degrees C) and the whole-body hyperthermia induced by FIR (WBH) (35-41 degrees C) on the growth of spontaneous mammary tumours of mice. A high mammary tumour strain of SHN virgin mice born on the normal rack or FIR rack were maintained on the respective racks until mammary tumour appearance. When the mammary tumour size reached approximately 7 mm, some mice in each group received no further treatment (Control and FIR groups, respectively) and the remaining mice received 3 hours of WBH each of 5 consecutive days (C + WBH and FIR + WBH groups, respectively). There was little difference between the control and FIR groups in the tumour growth over 10 days of examination. On the other hand, the tumour growth was inhibited significantly in both C + WBH and FIR + WBH groups and the degree of inhibition was similar. The data confirmed that the chronic exposure to FIR at ambient temperature has little effect on the growth of spontaneous mammary tumours in mice. WBH with FIR, however, strongly inhibited the tumour growth without deleterious side-effects, while chronic FIR irradiation itself again had little effect in this process. This WBH regimen may serve as a useful animal model for long-term studies of a noninvasive treatment of breast cancer.
PMID: 10628363 [PubMed – indexed for MEDLINE
1: Nippon Rinsho. 2007 Jun;65(6):1093-8.
[A new treatment: thermal therapy for chronic fatigue syndrome]
Thermal therapy using far-infrared ray dry sauna was performed for patients with chronic fatigue syndrome (CFS). Symptoms such as fatigue, pain, and low-grade fever were dramatically improved on two patients. And prednisolone administration was discontinued and became socially rehabilitated 6 months after discharge. On other 11 patients with CFS, physical symptoms such as fatigue and pain improved, too. Furthermore, we reported that repeated thermal therapy had relaxation effect and diminishes appetite loss and subjective complaints in mildly depressed patients. These results suggest that repeated thermal therapy may be a promising method for the treatment of CFS.
PMID: 17561703 [PubMed – indexed for MEDLINE